

# FIRST LIGHT 14 February 2020

# **RESEARCH**

Finolex Industries | Target: Rs 640 | +17% | BUY

Better PVC-EDC delta aids profitability - upgrade to BUY

Gujarat State Petronet | Target: Rs 375 | +58% | BUY

EBITDA underperforms; volume outlook improving

# **SUMMARY**

# Finolex Industries

Finolex Industries' (FNXP) revenue declined 8% YoY, with an 11% drop in PVC pipe and resin volumes. EBITDA margins expanded 140bps YoY to 19.8% mainly due to 335bps higher PVC resin margins, following a ~10% rise in the PVC-EDC delta. Management expects stronger pipe demand in Q4 due to a good crop, and has guided for double-digit growth in FY21. We roll forward to a Mar'21 TP of Rs 640 (earlier Rs 625) and upgrade the stock from ADD to BUY as current valuations of 17x FY22E EPS offer reasonable upside post the recent correction.

# Click here for the full report.

# **Gujarat State Petronet**

Gujarat State Petronet's (GUJS) Q3FY20 EBITDA underperformed estimates at Rs 3.8bn (+7.6% YoY) due to lower volumes (37mmscmd, -5.7% QoQ). Volumes were affected by reduced offtake from refineries – this could reverse from Q4FY20 following the recent crash in LNG prices. Power offtake is guided to pick up (from FY21) on an improved power demand outlook coupled with low LNG prices. We broadly maintain EPS estimates; our DCF-based TP increases to Rs 375 (from Rs 350) on higher value of investments (GUJGA).

# Click here for the full report.

# **TOP PICKS**

### LARGE-CAP IDEAS

Company	Rating	Target
Bajaj Finance	Buy	5,200
<u>Cipla</u>	Buy	570
Eicher Motors	Buy	25,000
Petronet LNG	Buy	400
Reliance Industries	Buy	1,860

#### **MID-CAPIDEAS**

Company	Rating	Target
Alkem Labs	Buy	2,870
Greenply Industries	Buy	205
<u>Laurus Labs</u>	Buy	510
Transport Corp	Buy	355
Ashok Leyland	Sell	68

Source: BOBCAPS Research

### **DAILY MACRO INDICATORS**

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	1.63	3bps	(21bps)	(107bps)
India 10Y yield (%)	6.48	1bps	(12bps)	(82bps)
USD/INR	71.35	(0.1)	(0.7)	(0.8)
Brent Crude (US\$/bbl)	29,551	0.9	2.2	15.7
Dow	2,927	0.9	(6.1)	7.6
Shanghai	41,566	0.8	(0.7)	15.4
Sensex	55.79	3.3	(13.1)	(12.3)
India FII (US\$ mn)	11 Feb	MTD	CYTD	FYTD
FII-D	12.5	1,440.5	(128.4)	2,815.7
FII-E	302.9	2,076.6	3,449.2	10,838.4

Source: Bank of Baroda Economics Research

# **BOBCAPS** Research

research@bobcaps.in





**BUY**TP: Rs 640 | ▲ 17%

# **FINOLEX INDUSTRIES**

Plastic Products

13 February 2020

# Better PVC-EDC delta aids profitability - upgrade to BUY

Finolex Industries' (FNXP) revenue declined 8% YoY, with an 11% drop in PVC pipe and resin volumes. EBITDA margins expanded 140bps YoY to 19.8% mainly due to 335bps higher PVC resin margins, following a ~10% rise in the PVC-EDC delta. Management expects stronger pipe demand in Q4 due to a good crop, and has guided for double-digit growth in FY21. We roll forward to a Mar'21 TP of Rs 640 (earlier Rs 625) and upgrade the stock from ADD to BUY as current valuations of 17x FY22E EPS offer reasonable upside post the recent correction.

Arun Baid research@bobcaps.in

**Extended monsoon dampens revenue:** FNXP's Q3 revenue decreased 8% YoY to Rs 7bn. The PVC resin segment declined 16% YoY with both volumes/ realisations slipping 11%/5% YoY. Revenue from PVC pipes & fittings also slipped 6% YoY, with volumes down 11% whereas realisations increased 5%. Pipe volumes were dampened by the extended monsoons during the quarter. Management expects increased pipe demand in Q4 due to a good crop season, followed by double-digit growth in FY21.

Higher PVC-EDC delta aids margins: Operating margins expanded 140bps YoY to 19.8% as raw material cost declined 360bps whereas employee cost/other expenses increased by 60bps/160bps – resulting in flat EBIDTA YoY. The PVC resin segment saw EBIT margins rise 335bps YoY due to softening ethylene di-chloride (EDC) prices, which led to a ~10% YoY increase in PVC-EDC delta to US\$ 589/mt (albeit down to US\$ 565/mt currently in February).

**Upgrade to BUY:** We broadly maintain earnings estimates and roll over to a Mar'21 TP of Rs 640, set at an unchanged 20x one-year forward P/E. The stock has corrected ~10% since Nov'19 and offers reasonable upside potential at current valuations of 16.8x FY22E EPS, leading us to upgrade our rating from ADD to BUY.

#### **KEY FINANCIALS**

Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
Total revenue (Rs mn)	27,378	30,913	32,859	35,633	38,856
EBITDA (Rs mn)	4,839	6,043	5,067	5,337	5,724
Adj. net profit (Rs mn)	2,993	3,857	3,556	3,735	4,037
Adj. EPS (Rs)	24.1	31.1	28.7	30.1	32.5
Adj. EPS growth (%)	(15.7)	28.9	(7.8)	5.0	8.1
Adj. ROAE (%)	11.7	14.4	13.4	13.4	13.7
Adj. P/E (x)	22.6	17.6	19.0	18.1	16.8
EV/EBITDA (x)	14.1	11.3	13.2	12.1	11.0

Source: Company, BOBCAPS Research

6

Source: NSE

# STOCK PERFORMANCE



Source: NSE





**BUY**TP: Rs 375 | ▲ 58%

# GUJARAT STATE PETRONET

Oil & Gas

13 February 2020

# EBITDA underperforms; volume outlook improving

Gujarat State Petronet's (GUJS) Q3FY20 EBITDA underperformed estimates at Rs 3.8bn (+7.6% YoY) due to lower volumes (37mmscmd, -5.7% QoQ). Volumes were affected by reduced offtake from refineries – this could reverse from Q4FY20 following the recent crash in LNG prices. Power offtake is guided to pick up (from FY21) on an improved power demand outlook coupled with low LNG prices. We broadly maintain EPS estimates; our DCF-based TP increases to Rs 375 (from Rs 350) on higher value of investments (GUJGA).

Rohit Ahuja | Harleen Manglani research@bobcaps.in

**Volumes decline:** Lower offtake from the refinery/petchem segment at 11.8mmscmd (–16% YoY) dampened volumes. Offtake increased from the CGD (10.7mmscmd, +35% YoY), power (5.9mmsmcd, +32% YoY) and fertiliser (4.06mmscmd, +7.3% YoY) segments. Management sees better potential ahead from the power segment as spot LNG prices remain low (<US\$ 3/mmbtu) and demand for power is improving.

RIL offtake steady for now: RIL continues to absorb ~9mmscmd (stable QoQ), implying its petcoke gasifiers are some time away from being commissioned. While GUJS could see volume loss (4-6mmscmd) once RIL's petcoke gasification plant comes online, this could be made up by incremental power and CGD demand in FY20-FY21.

Maintain BUY: GUJS has healthy volumes levers in place, viz. (a) planned connectivity to all the five LNG regasification terminals in Gujarat, and (b) an improving demand outlook from CGD and power. Commissioning of the Mundra LNG terminal is expected add to volumes from Q4FY20. At 11.3x FY22E EPS, valuations look attractive considering stronger volume visibility.

Ticker/Price	GUJS IN/Rs 238
Market cap	US\$ 1.9bn
Shares o/s	564mn
3M ADV	US\$ 1.8mn
52wk high/low	Rs 264/Rs 149
Promoter/FPI/DII	38%/16%/46%

Source: NSE

# STOCK PERFORMANCE



Source: NSE

#### **KEY FINANCIALS**

Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
Total revenue (Rs mn)	13,317	18,773	22,760	22,779	26,241
EBITDA (Rs mn)	11,478	15,426	17,073	16,770	19,090
Adj. net profit (Rs mn)	6,684	7,947	10,395	10,165	11,912
Adj. EPS (Rs)	11.9	14.1	18.4	18.0	21.1
Adj. EPS growth (%)	34.5	18.9	30.8	(2.2)	17.2
Adj. ROAE (%)	14.2	15.2	17.3	14.8	15.5
Adj. P/E (x)	20.1	16.9	12.9	13.2	11.3
EV/EBITDA (x)	11.8	9.6	9.4	9.3	7.9

Source: Company, BOBCAPS Research





# Disclaimer

#### Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

ADD - Expected return from >+5% to +15%

**REDUCE -** Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

#### Rating distribution

As of 31 January 2020, out of 85 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 50 have BUY ratings, 18 are rated ADD, 8 are rated REDUCE and 9 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

#### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

#### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

EQUITY RESEARCH 14 February 2020

#### **FIRST LIGHT**



We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

EQUITY RESEARCH 14 February 2020